Accelerating access to treatments for rare diseases

Area of Science:

• Pharmacology and Drug Development
• Regulatory Science
• Health Policy

Background:

• Recent policy changes and legislative incentives aim to accelerate the development of orphan drugs for rare diseases.
• Despite increased orphan drug designations, the number of these therapies reaching patients has not significantly improved.
• A gap persists between regulatory approval and patient access for rare disease treatments.

Purpose of the Study:

• To identify key areas where innovative approaches can enhance the regulatory approval process for orphan drugs.
• To explore strategies for improving patient access to treatments for rare diseases.
• To address the stagnation in the market availability of orphan drugs despite increased designations.

Main Methods:

• Review of current regulatory policies and legislative incentives for orphan drugs.
• Analysis of trends in orphan drug designations versus market approvals.
• Identification of potential novel regulatory pathways and access strategies.

Main Results:

• While orphan drug designations have risen, the rate of market approval remains a challenge.
• Specific regulatory hurdles and access barriers have been identified.
• Potential areas for novel approaches include expedited review pathways and innovative market access models.

Conclusions:

• Novel regulatory and access strategies are crucial to translate increased orphan drug designations into available treatments.
• Addressing the flat market entry rate requires a multi-faceted approach beyond initial designations.
• Facilitating regulatory approval and patient access is essential for rare disease therapeutics.